Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT05521984
- Locations
- 🇺🇸
Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri, United States
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
- Conditions
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 340
- Registration Number
- NCT05505994
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Medanta, The Medicity, India
- Target Recruit Count
- 250
- Registration Number
- NCT05457933
- Locations
- 🇮🇳
Division Of Endocrinology and Diabetes, Medanta The Medicity, Gurgaon, Haryana, India
Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 32
- Registration Number
- NCT05443932
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Tan Tock Seng Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05440591
- Locations
- 🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 152
- Registration Number
- NCT05429593
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Brandenburg, Germany
🇩🇪Parexel International GmbH, Berlin, Germany
Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 40
- Registration Number
- NCT05420285
- Locations
- 🇫🇷
Pitié-Salpêtrière Hospital, Paris, France
Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Target Recruit Count
- 100
- Registration Number
- NCT05418465
- Locations
- 🇨🇳
The First Affiliated Hospital of Dalian medical university, Dalian, Liaoning, China
Obesity Treatment to Improve Diabetes
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Dasman Diabetes Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05390307
- Locations
- 🇰🇼
Dasman Diabetes Institute, Kuwait City, Al Asimah, Kuwait
Cognitive Protective Effect of Newer Antidiabetic Drugs
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05347459
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.